Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
Bioxytran has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA), to initiate clinical trials of ProLectin-M for the treatment of mild to moderate COVID-19 in standard risk patients.
August 24, 2023